Results 81 to 90 of about 1,153,423 (284)

Reliability and validity of the Geriatric Self-Care Scale among Chinese older adults

Annals of Medicine
Background Although the Geriatric Self-Care Scale (GSS) has been widely used in community investigations in China, its reliability and validity have yet to be analyzed.Objectives This study aimed to examine the reliability and validity of the GSS in ...
Hongji Zeng, Weijia Zhao, Rui Wang, Xin’ao Wang, Pengchao Luo, Xuyang Zhang, Xi Zeng   +6 more
doaj   +1 more source

The stroke oxygen pilot study: a randomized control trial of the effects of routine oxygen supplementation early after acute stroke--effect on key outcomes at six months [PDF]

, 2013
Introduction: Post-stroke hypoxia is common, and may adversely affect outcome. We have recently shown that oxygen supplementation may improve early neurological recovery. Here, we report the six-month outcomes of this pilot study.
AB Singhal, AM Rowat, Anushka Warusevitane, B Indredavik, C Collin, C Counsell, C Roffe, C Roffe, CC Wright, Christine Roffe, Christoph Kleinschnitz, DM Bravata, F Nouri, FB Young, Frank Lally, G Sulter, G Teasdale, J Bamford, J Ellul, J Nuutinen, JB Cabello, JC van Swieten, JH Kilgannon, Julius Sim, K Ali, K Ali, KF Schulz, Khalid Ali, KR Lees, M Dennis, M Dennis, Martin Allen, OM Rønning, P Appelros, P Dolan, P Sandercock, P Thorvaldsen, Sarah Pountain, SC Lewis, Sheila Sills, T Brott, Tracy Nevatte, Y Silva   +42 more
core   +3 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Predictors of costs in dementia in a longitudinal perspective. [PDF]

PLoS ONE, 2013
OBJECTIVE: To analyse predictors of costs in dementia from a societal perspective in a longitudinal setting. METHOD: Healthcare resource use and costs were assessed retrospectively using a questionnaire in four waves at 6-month intervals in a sample of ...
Hanna Leicht, Hans-Helmut König, Nina Stuhldreher, Cadja Bachmann, Horst Bickel, Angela Fuchs, Kathrin Heser, Frank Jessen, Mirjam Köhler, Melanie Luppa, Edelgard Mösch, Michael Pentzek, Steffi Riedel-Heller, Martin Scherer, Jochen Werle, Siegfried Weyerer, Birgitt Wiese, Wolfgang Maier, AgeCoDe study group   +18 more
doaj   +1 more source

PROFILES OF RECREATIONAL ACTIVITIES OF DAILY LIVING (RADL) IN PATIENTS WITH MENTAL DISORDERS [PDF]

, 2009
Background: Activities of daily living, play a key role in the measurement of functional health as defined by the International Classification of Functioning, Disability and Health (ICF) and in prevention and treatment of mental or somatic illnesses ...
B. Geiselmann, G. Gehrke, Michael Linden
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Functional capacity and associated factors among longevous senior individuals living in community: a population study in Northeastern Brazil

Fisioterapia e Pesquisa, 2014
The objective of this study was to determine the prevalence of impaired functional capacity and the associated factors in longevous elderly individuals from a city in the countryside of Northeastern Brazil.
Thaís Alves Brito, Marcos Henrique Fernandes, Raildo da Silva Coqueiro, Cleber Souza de Jesus, Roberta Freitas   +4 more
doaj   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Behavioral Competence Among Community Dwelling Older People with Disability in Basic Activities of Daily Living.

Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 2000
This study observed the status of independence in behavioral competence among older people who have any disability in basic activities of daily living (BADL) living in a rural community in Japan. Study participants (N = 76) who were regarded as bedridden were surveyed by means of a questionnaire in July to August 1996.
T, Ishizaki, S, Watanabe, T, Suzuki, H, Shibata, H, Yoshida, S, Yasumura, N, Niino   +6 more
openaire   +3 more sources

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source